Retatrutide

(L Y3437943) Retatrutide is a multi-receptor peptide agonist targeting GLP-1, GIP, and glucagon receptors, developed for the treatment of obesity and type 2 diabetes. By simultaneously modulating these three pathways, Retatrutide provides a comprehensive metabolic approach, promoting weight loss, glycemic control, improved lipid metabolism, and enhanced energy expenditure. Its once-weekly subcutaneous administration improves patient adherence while maintaining therapeutic efficacy. Mechanism of Action: GLP-1 receptor activation: Stimulates glucosedependent insulin secretion, suppresses appetite, and improves glycemic control. GIP receptor activation: Enhances insulin response and supports fat metabolism. Glucagon receptor activation: Increases energy expenditure and promotes fatty acid oxidation. Synergistic effects: Dual and triple receptor engagement provides superior weight loss, cardiometabolic benefits, and metabolic fl exibility compared to single-agent therapies.